Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and Tissue Data Confirm NaviCap Platform Delivers Topically Through the Entire Colon, With Lower Systemic Concentrations, as Desired'
Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and Tissue Data Confirm NaviCap Platform Delivers Topically Through the Entire Colon, With Lower Systemic Concentrations, as Desired'
Biora Therapeutics宣佈來自Bt-600試驗的補充數據報告；稱“藥物動力學和組織數據證實NaviCap平台可以通過整個結腸局部輸送，系統濃度更低，達到預期效果。”
Biora Therapeutics Announces Presentation Of Supplemental Data From Phase 1 BT-600 Trial; Says 'Pharmacokinetic and Tissue Data Confirm NaviCap Platform Delivers Topically Through the Entire Colon, With Lower Systemic Concentrations, as Desired'
Biora Therapeutics宣佈來自Bt-600試驗的補充數據報告；稱“藥物動力學和組織數據證實NaviCap平台可以通過整個結腸局部輸送，系統濃度更低，達到預期效果。”
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。